[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2013002121A - Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. - Google Patents

Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Info

Publication number
MX2013002121A
MX2013002121A MX2013002121A MX2013002121A MX2013002121A MX 2013002121 A MX2013002121 A MX 2013002121A MX 2013002121 A MX2013002121 A MX 2013002121A MX 2013002121 A MX2013002121 A MX 2013002121A MX 2013002121 A MX2013002121 A MX 2013002121A
Authority
MX
Mexico
Prior art keywords
kcnq2
carboxamides
modulators
substituted quinoline
relates
Prior art date
Application number
MX2013002121A
Other languages
English (en)
Inventor
Wolfgang Schroeder
Sven Kuehnert
Gregor Bahrenberg
Achim Kless
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2013002121A publication Critical patent/MX2013002121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se relaciona con quinolina-3-carboxamidas sustituidas de la fórmula (I) como moduladores de KCNQ2/3 para uso en el tratamiento y/o profilaxis de dolor y enfermedades y/o trastornos relacionados. (ver fórmula).
MX2013002121A 2010-08-27 2011-08-26 Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. MX2013002121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008924 2010-08-27
PCT/EP2011/004279 WO2012025238A1 (en) 2010-08-27 2011-08-26 Substituted quinoline-3-carboxamides as kcnq2/3 modulators

Publications (1)

Publication Number Publication Date
MX2013002121A true MX2013002121A (es) 2013-04-03

Family

ID=43302061

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002121A MX2013002121A (es) 2010-08-27 2011-08-26 Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Country Status (10)

Country Link
US (1) US8445512B2 (es)
EP (1) EP2609085A1 (es)
JP (1) JP5887346B2 (es)
AR (1) AR082734A1 (es)
AU (1) AU2011295407B2 (es)
BR (1) BR112013004721A2 (es)
CA (1) CA2804824A1 (es)
MX (1) MX2013002121A (es)
TW (1) TWI565465B (es)
WO (1) WO2012025238A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
US8653101B2 (en) 2010-08-27 2014-02-18 Gruenenthal Gmbh Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators
CA2809287C (en) 2010-08-27 2018-05-22 Gruenenthal Gmbh Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
JP5976649B2 (ja) 2010-09-01 2016-08-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換１−オキソ−ジヒドロイソキノリン−３−カルボキサミド
CN104994857A (zh) 2012-10-11 2015-10-21 格吕伦塔尔有限公司 Tspo介导的疾病和/或障碍的治疗和/或预防
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
MX2015006689A (es) 2012-11-28 2015-08-20 Grünenthal GmbH Carboxamidas especificas como moduladores de kcnq2/3.
CA2892652A1 (en) * 2012-11-28 2014-06-05 Grunenthal Gmbh Heteroquinoline-3-carboxamides as kcnq2/3 modulators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482596A1 (fr) 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
US4798619A (en) * 1980-06-02 1989-01-17 American Cyanamid Co. 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents
DE3111934A1 (de) 1981-03-26 1982-10-07 Bayer Ag, 5090 Leverkusen Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung
FR2509728A1 (fr) 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
DE3210063A1 (de) * 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DE3211934A1 (de) 1982-03-31 1983-10-13 Hoechst Ag, 6230 Frankfurt Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
FR2532939A1 (fr) * 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
EP0634169B1 (en) * 1993-06-29 2000-01-05 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives and their use in the manufacture of a medicament for the treatment of osteoporosis
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
CA2545092C (en) 2003-11-24 2010-08-17 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
WO2007070359A2 (en) 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
CA2651871A1 (en) 2006-05-10 2007-11-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8134004B2 (en) 2006-07-11 2012-03-13 Pfizer Inc. Substituted N-bicyclicalkyl bicycliccarboxyamide compounds
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
ATE520651T1 (de) 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
US20080221161A1 (en) 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
WO2008121850A2 (en) * 2007-03-30 2008-10-09 University Of Rochester Small-molecule modulators of melanin expression
SI2350093T1 (sl) 2008-10-24 2012-11-30 Gruenenthal Chemie Substituirani tetrahidrotienopiridini kotKCNQ modulatorji za zdravljenje bolečine epilepsije in urinske inkotinence
US20100125091A1 (en) * 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
WO2010094644A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use

Also Published As

Publication number Publication date
AR082734A1 (es) 2012-12-26
WO2012025238A1 (en) 2012-03-01
CA2804824A1 (en) 2012-03-01
TW201210596A (en) 2012-03-16
AU2011295407B2 (en) 2016-01-21
AU2011295407A1 (en) 2013-01-10
BR112013004721A2 (pt) 2016-05-17
EP2609085A1 (en) 2013-07-03
US8445512B2 (en) 2013-05-21
TWI565465B (zh) 2017-01-11
JP5887346B2 (ja) 2016-03-16
JP2013536212A (ja) 2013-09-19
US20120053204A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
IN2015DN01156A (es)
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
PH12015501661A1 (en) Pyridone amides as modulators of sodium channels
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
IN2014CN04014A (es)
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
EP2814491A4 (en) FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2016007956A (es) Pirrol carboxamidas fluorometil-sustituidas como bloqueadores del canal de calcio de cav2.2.

Legal Events

Date Code Title Description
FG Grant or registration